MoFo News Item

MoFo advises Carlsmed in its $30M Series B Round

09 May 2022

MoFo advised Carlsmed in the completion of its $30 million Series B financing round. Carlsmed’s mission is to improve outcomes and decrease the cost of healthcare for spine surgery and beyond. The company’s aprevo® devices are personalized to improve the standard of care for the surgical treatment of adults with spinal malalignment. Carlsmed uses patient data and proprietary digital technologies to create aprevo® spine fusion devices to align with the surgeon’s goals for each patient. The company is planning to use the financing to scale the commercialization of aprevo®, Carlsmed’s FDA cleared personalized surgical devices.

The funding round was led by B Capital Group with additional participation from existing investors, including U.S. Venture Partners, The Vertical Group, Cove Fund and Wavemaker Three-Sixty Health.

The MoFo team included San Diego corporate attorneys Jim Krenn, Brennan Brodersen, Carey Hughes, and Brooke Maker.



Unsolicited e-mails and information sent to Morrison & Foerster will not be considered confidential, may be disclosed to others pursuant to our Privacy Policy, may not receive a response, and do not create an attorney-client relationship with Morrison & Foerster. If you are not already a client of Morrison & Foerster, do not include any confidential information in this message. Also, please note that our attorneys do not seek to practice law in any jurisdiction in which they are not properly authorized to do so.